Mlkl mabc604

Manufactured by Merck Group

MLKL (MABC604) is a laboratory equipment product manufactured by Merck Group. It is a device designed for specific technical functions in research and laboratory settings. The core function of MLKL (MABC604) is to perform a specialized task, but a detailed description cannot be provided in a concise, unbiased, and factual manner without the risk of interpretation or extrapolation.

Automatically generated - may contain errors

Lab products found in correlation

Nec 1a, by Genentech (1 mentions) Gne684, by Genentech (1 mentions) Ripk1 38 rip, by BD (1 mentions) Gsk 843, by GlaxoSmithKline (1 mentions) Mda 5 d74e4, by Cell Signaling Technology (1 mentions) Cleaved caspase 3 clone d3e9, by Cell Signaling Technology (1 mentions) Anti fkbp12, by Thermo Fisher Scientific (1 mentions) Caspase 3 9662, by Cell Signaling Technology (1 mentions) Anti flag m2, by Merck Group (1 mentions)

Close spelling variants of this product

MABC604 (8 citations)

2 protocols using mlkl mabc604

Investigating Necroptosis Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human recombinant TNF, Nec-1a, BV6, GNE684, and GSK547 were all synthesized at Genentech. The primary antibodies used were directed against: RIP1 (610459), pJNK (562480) (BD Biosciences); IκBα (9242), HSP90 (4874), A20 (5630), caspase-8 (9746), human pRIP1 S166 (65746), and RIP3 (13526) (Cell Signaling Technology); mouse pMLKL S345 (ab196436) and human c-IAP2 (ab32059) (Abcam); MLKL (MABC604) (Millipore); mouse c-IAP2 and RIP3 (Genentech).

Patel S., Webster J.D., Varfolomeev E., Kwon Y.C., Cheng J.H., Zhang J., Dugger D.L., Wickliffe K.E., Maltzman A., Sujatha-Bhaskar S., Bir Kohli P., Ramaswamy S., Deshmukh G., Liederer B.M., Fong R., Hamilton G., Lupardus P., Caplazi P., Lee W.P., van Lookeren Campagne M., Johnson A., McKenzie B.S., Junttila M.R., Newton K, & Vucic D. (2019). RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death and Differentiation, 27(1), 161-175.

+ Open protocol

+ Expand

Multimodal Analysis of Cell Death Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Where indicated, the following drugs were used at the listed concentrations: 50 μM zVAD (SM Biochemicals), 100nM GSK’843 (GlaxoSmithKline).
The following antibodies were used for Western Blots and immunoprecipitations: ADAR1 (15.8.6) SantaCruz, ZBP1 (Zippy-1) AdipoGen, actin (13E5) Cell Signaling Technology, MDA5 (D74E4) Cell Signaling Technologies, p-RIPK3 (GEN135–35-9), Genentech, RIPK3 (1G6.1.4) Genentech, or RIPK3 (2283) ProSci, p-MLKL (D6E3G) Cell Signaling Technologies, MLKL (MABC604) Millipore, Caspase-3 (9662) Cell Signaling Technologies, Cleaved Capsase-3 (9661) Cell Signaling Technologies, RIPK1 (38/RIP) BD Biosciences, anti-FLAG (M2) Sigma, anti-FKBP12, Thermo Fisher (PA1–026A). Iba1 (Cat no. 019–19741) Wako-Chem, Cleaved Caspase 3 (Clone D3E9) Cell Signaling Technologies were used in immunohistochemical analysis.
The following antibodies were used for flow cytometry analysis of splenocytes: FITC anti-CD19 (clone 1D3; BD Biosciences) PerCP-Cy5.5 anti-CD3e (clone 145–2C11; BD Biosciences), PE-Cy7 anti-Ly6C (clone HK1.4; Biolegend), APC anti-F4/80 (clone BM8; eBioscience), AF700 anti-Ly6G (clone 1A8; Biolegend), APC-Cy7 anti-NK1.1 (clone PK136; BD Biosciences), BV510 anti-CD8a (clone 53–6.7; BD Biosciences); BV605 anti-CD4 (clone RM4–5; BD Biosciences), BV650 anti-CD11b (clone M1/70; Biolegend), and BUV395 anti-CD45.2 (clone 104; BD Biosciences).

Hubbard N.W., Ames J.M., Maurano M., Chu L.H., Somfleth K.Y., Gokhale N.S., Werner M., Snyder J.M., Lichauco K., Savan R., Stetson D.B, & Oberst A. (2022). ADAR1 mutation causes ZBP1-dependent immunopathology. Nature, 607(7920), 769-775.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!